Institut Bordet - Retour à la page d'accueil
en
I want to donate to research

Evandro De Azambuja

Department : Medical oncology, Clinical Trials Support Unit (CTSU)

Publications

Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.

Authors : Pondé N, Amaye L, Lambertini M, Paesmans M, Piccart M, de Azambuja E
Year : 2020
Journal : Eur J Cancer

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Authors : Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M
Year : 2019
Journal : Clin Cancer Res

Oncofertility counselling in premenopausal women with HER2-positive breast cancer.

Authors : Lambertini M, Demeestere I, Viglietti G, de Azambuja E
Year : 2019
Journal : Oncotarget

Pertuzumab in HER2-positive early breast cancer: current use and perspectives.

Authors : Eiger D, Pondé NF, de Azambuja E
Year : 2019
Journal : Future Oncol

ER+/HER2+ breast cancer: are we really de-escalating?

Authors : de Azambuja E, Piccart-Gebhart M
Year : 2019
Journal : Ann Oncol

More publications »

Follow us!

Youtube

Exclusive images of the new Jules Bordet Institute!

Watch the video and discover the major project for the new Jules Bordet Institute. Magnificent images of the construction work on the   80,000 m² dedicated exclusively to cancer are accompanied by explanations on how the project was conceived to combine excellence of patient care with optimal well-being for patients and care staff.